TICKERNERD
Menu
ANROANROHealthcare · Biotechnology

ANRO Stock Forecast: Alto Neuroscience, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$32
−0.50% on the day

The 11 Wall Street analysts covering Alto Neuroscience, Inc. hold a median 12-month price target of $37 — +15.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 55 of 100 as at 15 Aug 2026 — in the upper half.

Market cap
$1.3B
Ticker Nerd rank
55 / 100
Median analyst target
$37
Analysts covering
11
Total return, dividends reinvested
1W
+12.1%
1M
+15.6%
YTD
+80.6%
1Y
+930.1%
From 52W high
−0.5%
From 52W low
+930.1%
$3
$32
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ANRO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Alto Neuroscience, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
55 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
100
Value
64
Accruals
57
Revisions
55
Issuance
53
Quality
44
Size
43
Growth
36
Volatility
11

Momentum (100): The shares have been drifting up relative to others.

Volatility (11): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ANRO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ANRO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50Oct 25Jan 26Apr 26Jul 26ANROHigh $50Median $37Low $26

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says11 analysts
10 Buy1 Hold0 Sell
Low $26Median $37High $50

The green dot is the last close — the median target sits +15.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
13 Aug 2026BTIGMaintainsBuy$28 → $37
13 Aug 2026WedbushMaintainsNeutral$24 → $26
18 May 2026BairdMaintainsOutperform$38 → $36
18 May 2026BairdMaintainsOutperform—
14 May 2026WedbushMaintainsNeutral—
14 May 2026WedbushMaintainsNeutral$21 → $24
11 May 2026HC Wainwright & Co.ReiteratesBuy$50
11 May 2026HC Wainwright & Co.ReiteratesBuy—
11 May 2026HC Wainwright& Co.ReiteratesBuy—
22 Apr 2026Chardan CapitalMaintainsBuy—
2 Apr 2026BairdMaintainsOutperform—
2 Apr 2026Chardan CapitalMaintainsBuy—
2 Apr 2026HC Wainwright & Co.ReiteratesBuy—
2 Apr 2026Jones TradingMaintainsBuy—
2 Apr 2026WedbushMaintainsNeutral—
18 Mar 2026BairdMaintainsOutperform—
17 Mar 2026Chardan CapitalMaintainsBuy—
17 Mar 2026WedbushMaintainsNeutral—
17 Feb 2026BTIGMaintainsBuy—
5 Jan 2026Chardan CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ANRO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ANRO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Alto Neuroscience, Inc. (ANRO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−14.7×

Cheaper than 94% of US stocks

Price / sales
—
Price / book
5.1×

Cheaper than 21% of US stocks

EV / EBITDA
−11.9×

Cheaper than 85% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−49.2%

Higher than 21% of US stocks

Return on assets
−26.8%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ANRO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ANROAlto Neuroscience, Inc.$1.3B
55
CGEMCullinan Therapeutics, Inc.$1.3B
71
CRVSCorvus Pharmaceuticals, Inc.$1.2B
55
MGTXMeiragtx Holdings plc$1.3B
80
DRTSAlpha Tau Medical Ltd.$1.3B
17
REPLReplimune Group, Inc.$1.2B
34
IMTXImmatics NV$1.3B
57

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Alto Neuroscience, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ANRO news & analysis

Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Business Wire · 12 Aug 2026positive

Alto Neuroscience reported its financial results for the quarter ended June 30, 2026, and highlighted recent progress across its pipeline of clinical-stage product candidates. The company noted that the second quarter strengthened the case for ALTO-207 and management's conviction in its opportunity.

Why it matters — ANRO watchers would care because the update reinforces management confidence in lead candidate ALTO-207 and signals continued pipeline progress for a clinical-stage neuropsychiatric precision-medicine company.

Alto Neuroscience: Buy ALTO-207 Advancement TRD And Other Expansion Indications

Seeking Alpha · 3 Aug 2026positive

A Seeking Alpha article highlights Alto Neuroscience's ALTO-207, a pramipexole/ondansetron combination for treatment-resistant depression, with phase 2b topline data expected in 2H 2027 and possible phase 3 initiation by early 2027. The piece notes the company's strong cash reserves and diversified, biomarker-driven pipeline, even after ALTO-100's phase 2b failure in MDD, as supporting factors for its positive rating on the stock.

Why it matters — ANRO watchers would care because the ALTO-207 timeline and pipeline breadth are central to the company's outlook after the ALTO-100 setback.

FAQ

Frequently asked questions about ANRO stock

What is the ANRO stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Alto Neuroscience, Inc. have a median 12-month price target of $37, with estimates ranging from $26 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ANRO stock a buy right now?

Of the 11 analysts covering Alto Neuroscience, Inc., 10 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alto Neuroscience, Inc. 55 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ANRO?

As at 15 Aug 2026, Alto Neuroscience, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (100 of 100).

Will ANRO stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +15.1% from the last close, and Ticker Nerd's factor model ranks Alto Neuroscience, Inc. 55 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ANRO stock forecast for 2030?

No analyst covering Alto Neuroscience, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANRO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $26 to $50 over the next 12 months.

How has ANRO stock performed over the past year?

Alto Neuroscience, Inc. returned +930.1% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Alto Neuroscience, Inc. do?

Alto Neuroscience Inc. is a biotechnology company that focuses on developing precision therapeutics for psychiatric disorders.

What is the latest news on ANRO?

The most recent item we track (Business Wire, 12 Aug 2026): "Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights". Alto Neuroscience reported its financial results for the quarter ended June 30, 2026, and highlighted recent progress across its pipeline of clinical-stage product candidates. The company noted that the second quarter strengthened the case for ALTO-207 and management's conviction in its opportunity.

Company

About Alto Neuroscience, Inc.

Alto Neuroscience Inc. is a biotechnology company that focuses on developing precision therapeutics for psychiatric disorders. The company's primary objective is to utilize advanced neurobiological insights and digital tools to tailor treatments for conditions like depression, anxiety, and other mental health disorders. Utilizing cutting-edge techniques such as AI-driven patient profiling and biomarker-based approaches, Alto Neuroscience seeks to enhance the efficacy of mental health treatments by ensuring more personalized and targeted solutions. This approach represents a significant innovation in the mental health sector by moving away from the one-size-fits-all model of psychotropic medications. In terms of market impact, Alto Neuroscience operates at the intersection of biotechnology and digital health, playing a pivotal role in the evolution of psychiatric treatment paradigms. The company's efforts contribute to the broader healthcare landscape by potentially improving patient outcomes and reducing trial and error in mental health medication management.

CEO Dr. Amit Etkin M.D., Ph.D. · 68 employees · United States · https://www.altoneuroscience.com